Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -23%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
SANIGEN
188260 · KOSDAQ₩1,999-3.43%
2026-09-04 closeSANIGEN last closed at ₩1,999 (-3.43%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
Strong RS 70 · top 30%
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
F
Overall: 상사,자본재 70/74 · top 95%
Factor composite · relative position in sector
PER — · PBR 1.42 — own-history percentile 38/100 · —/100
Open self-history band
PER38/100
PBR—/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -2.92
Distress
Grey
Safe
- Altman Z''
- -2.92
- Beneish M-Score
- -1.67
- Sloan accrual
- 2.23%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityWarning
OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 49% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05상사,자본재
This stock is in 상사,자본재: revenue rank 67 of 73, share 0%.
67 / 730%revenue share
Who dominates this industry?
- 1SK29.2%
- 2한화13%
- 3CJ10.2%
- 4삼성물산9.8%
- 5포스코인터내셔널7.6%
- 6세니젠0%
Concentration
DistributedCR3 52.4%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
MixedConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 10.17
- Direction
- 확대
- Level
- 보통
- Years
- 6
Value lens
- P90/P10
- 11.5
- Median P/B
- 1.18
- Level
- 넓음
- n
- 58
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -21.3%
- Interest coverage
- -24.7x
- Return on equity (ROE)
- -49.7%
Operating margin −5pp
Operating lossInterest coverageBase -24.7x adverse case -30.5x
Return on equity (ROE)Base -49.7% adverse case -63.9%
Revenue −15%
Interest coverage riskInterest coverageBase -24.7x adverse case -21x
Return on equity (ROE)Base -49.7% adverse case -44.6%
Interest rate +2pp
Interest coverage riskInterest coverageBase -24.7x adverse case -15.2x
Return on equity (ROE)Base -49.7% adverse case -53.3%
Interest coverage limit
Already below the limit by 22.1ppInterest coverage limit at an operating margin of 0.9%
Interest expense coverage threshold
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 지씨파트너스54.06%2026-07-10 · 증감 +1.96%p
- 박정웅18.09%2026-06-09 · 증감 -15.19%p
Connections
AI-extracted related companies · for reference
Suppliers
바이오소재·진단원료
Competitors
Same theme
키트 제조·진단 시약 산업체외진단감염병 진단
Recent filings
SANIGEN's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About SANIGEN
- What technical signals does SANIGEN (188260) have?
- SANIGEN current technical signals: no active technical signal.
- Is SANIGEN a cup-and-handle pattern?
- No. SANIGEN has no valid cup-and-handle signal right now.
- What are SANIGEN's financials and valuation?
- SANIGEN's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy